CONFERENCE COVERAGE SERIES
Alzheimer's Association International Conference 2012
Vancouver, British Columbia, Canada
14 – 19 July 2012
Experimental α7 Agonist Meets Cognitive and Clinical Endpoints
Researchers reported that EVP-6124 improved cognition and function in a trial of 409 people with mild to moderate Alzheimer’s disease...
New Assays for Aβ Oligomers in CSF Claim Femtogram Sensitivity
At the Alzheimer’s Association International Conference, two companies presented their progress toward oligomer-measuring assays...
Q&A With Roche’s CNS Leader Luca Santarelli
Gabrielle Strobel met up with Luca Santarelli, who has moved into drug discovery research at Roche/Genentech and now oversees the AD therapy development program, among others...
When Is a C9ORF72 Repeat Expansion Not a C9ORF72 Repeat Expansion?
Researchers have discovered a mutation within the mutation that is the C9ORF72 expansion causing amyotrophic lateral sclerosis and frontotemporal dementia...
Wave of New BACE Inhibitors Heading to Phase 2
At long last, drug developers' efforts in developing β-secretase (BACE1) inhibitors are starting to pay off...
Researchers Join to Draw Posterior Cortical Atrophy Out of Shadows
Researchers called the first in-person gathering of a newly formed working group on posterior cortical atrophy (PCA)...
Cochrane Asks for Field’s Input on Draft Reporting Standards
Most researchers agree that clinical dementia papers need reporting standards, especially when it comes to diagnostic tests...
Can We All Agree on How to Draw a Hippo(campus)?
As to precisely where the hippocampus starts and stops on a magnetic resonance image, researchers have little consensus...
Collaborative Umbrella CAPs Three Prevention Trial Initiatives
A new group called CAP introduced itself, then three prevention initiatives gave a brief update and stood for extended discussion with the audience...
On Risk, Benefit, and More, Prevention Initiatives Take Questions
Leaders of three ongoing preclinical treatment initiatives answered questions from a packed audience...
In Big Picture, Familial AD’s Biomarker Data Resemble LOAD
Researchers with eyes peeled toward prodromal AD probably see the diagram of the field’s five most validated markers in their sleep...
Dimmed Network Connections May Explain Metabolic Shortfall
Researchers think amyloid deposition, synaptic disruption, and neuronal glucose metabolism are all somehow connected as Alzheimer's disease unfolds...
To Reveal or Not to Reveal? New Data on the Question
Researchers are trying to tackle whether and how to disclose genetic and biomarker data to people in both routine clinical care and research settings...
iPSC Disease Models Up and Coming for AD, Down’s, ALS
Patient-derived cells may illuminate the underlying biology of human disease at the cellular level in a way animals cannot...
GWAS Mega-Meta Yields More Risk Genes, BIN1 Binds Tau?
A huge meta-analysis of GWAS data is turning up additional genes for late-onset AD...
Night Owl? Early Bird? Good Night’s Sleep May Protect the Brain
Both epidemiological and lab findings converge to point a finger at sleep in connection to cognitive decline...
Plaque May Quash Seesawing CSF Aβ Levels
Aβ levels in cerebrospinal fluid (CSF) and plasma seem to rise and fall considerably during a single day...
Could Sortilin Be a Sweet Spot for FTD Therapy?
Frontotemporal dementia was the topic of a presentation describing why sortilin, the receptor for growth factor progranulin, is a “sweetheart of targets” for FTD...